^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KZR-540
i
Other names: KZR-540, KZR540, KZR 540
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Kezar
Drug class:
Sec61 inhibitor
Related drugs:
over3years
KZR-540 is a novel oral small molecule inhibitor of Sec61 cotranslational translocation that potently and selectively blocks PD-1 expression (SITC 2022)
Targeting Sec61 with small molecule inhibitors such as KZR-261, currently in a clinical trial for solid tumors ( NCT05047536 ), has anti-tumor effects through inhibiting the expression of multiple therapeutic targets, including PD-1, in preclinical models. Future studies will examine whether there is an enhanced anti-tumor response in a tumor model. Ethics Approval Animal studies were approved by the Institutional Animal Use and Care Committee.
PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • SEC61G (SEC61 Translocon Subunit Gamma)
|
PD-1 expression
|
KZR-261 • KZR-540
Share via
